Latest COGT reports update at 2024-05-07: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Cogent Biosciences COGT

$ 7.92 4.21%

Cogent Biosciences Balance Sheet 2011-2024 | COGT

Annual Balance Sheet Cogent Biosciences

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-34.4 M	-120 M	-218 M	-237 M	-31.4 M	-55.7 M	-28.3 M	-41.3 M	-	-	-	-	-
Long Term Debt	17.5 M	18.2 M	831 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.39 M	1.42 M	2.32 M	2.05 M	1.62 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	3.16 M	4.41 M	748 K	9.62 M	14.4 M	-	-	-	-	-
Total Current Liabilities	38.2 M	26.8 M	17.1 M	13.1 M	13.2 M	24.9 M	-	-	-	-	-	-	-
Total Liabilities	55.6 M	45.1 M	17.9 M	16.2 M	17.7 M	25.7 M	20.8 M	23.2 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	1.32 M	17.9 M	6.89 M	5.96 M	-	-	-	-	-
Retained Earnings	-604 M	-411 M	-271 M	-199 M	-124 M	-92.1 M	-51.3 M	-25.8 M	-	-	-	-	-
Total Assets	313 M	301 M	232 M	251 M	49.4 M	85.9 M	49.1 M	75.6 M	-	-	-	-	-
Cash and Cash Equivalents	53.2 M	140 M	221 M	242 M	37.4 M	55.7 M	29.6 M	-	-	-	-	-	-
Book Value	258 M	256 M	214 M	235 M	31.8 M	60.2 M	28.3 M	52.4 M	-	-	-	-	-
Total Shareholders Equity	258 M	256 M	214 M	235 M	31.8 M	60.2 M	-48.8 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Cogent Biosciences

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	17.1 M	17.5 M	17.8 M	18.2 M	18.5 M	18.2 M	18.1 M	19 M	1.13 M	831 K	1.44 M	2.03 M	2.6 M	3.16 M	3.16 M	3.16 M	3.16 M	4.41 M	4.41 M	4.41 M	4.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	53.8 M	55.6 M	52.5 M	43.9 M	39.6 M	45.1 M	41.6 M	46.7 M	19 M	17.9 M	18.1 M	15.7 M	10.8 M	16.2 M	16.2 M	16.2 M	16.2 M	17.7 M	17.7 M	17.7 M	17.7 M	25.7 M	25.7 M	25.7 M	25.7 M	20.8 M	20.8 M	20.8 M	20.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	312 K	841 K	1.32 M	1.32 M	1.32 M	1.32 M	17.9 M	20.1 M	20.4 M	17.5 M	6.89 M	-	6.89 M	6.89 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-662 M	-604 M	-549 M	-494 M	-450 M	-411 M	-372 M	-337 M	-302 M	-271 M	-246 M	-227 M	-210 M	-199 M	-199 M	-199 M	-199 M	-124 M	-124 M	-124 M	-124 M	-92.1 M	-92.1 M	-92.1 M	-92.1 M	-51.3 M	-51.3 M	-51.3 M	-51.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	476 M	313 M	355 M	392 M	263 M	301 M	332 M	366 M	207 M	232 M	215 M	229 M	238 M	251 M	251 M	251 M	251 M	49.4 M	49.4 M	49.4 M	49.4 M	85.9 M	85.9 M	85.9 M	85.9 M	49.1 M	49.1 M	49.1 M	49.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	216 M	53.2 M	86.8 M	214 M	162 M	140 M	142 M	327 M	192 M	220 M	204 M	219 M	231 M	243 M	242 M	242 M	242 M	37.4 M	37.4 M	37.4 M	37.4 M	55.7 M	55.7 M	55.7 M	55.7 M	28.3 M	28.3 M	28.3 M	28.3 M	42.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	422 M	258 M	303 M	348 M	224 M	256 M	290 M	319 M	188 M	214 M	197 M	213 M	227 M	235 M	235 M	235 M	235 M	31.8 M	31.8 M	31.8 M	31.8 M	60.2 M	60.2 M	60.2 M	60.2 M	28.3 M	28.3 M	28.3 M	28.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	422 M	258 M	303 M	348 M	224 M	256 M	290 M	319 M	188 M	214 M	197 M	213 M	227 M	235 M	235 M	235 M	235 M	31.8 M	31.8 M	31.8 M	31.8 M	60.2 M	60.2 M	60.2 M	60.2 M	-48.8 M	-48.8 M	-48.8 M	-48.8 M	-24.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency